Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

OP10F Anti-c-Myc (Ab-1) Mouse mAb (9E10) Fluorescein Conjugate

MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.
View Products on Sigmaaldrich.com
OP10F
  
Purchase on Sigma-Aldrich

Overview

Replacement Information

Key Spec Table

Species ReactivityHostAntibody Type
H, M, RMMonoclonal Antibody
Description
Overview

This product has been discontinued.



Recognizes the ~60-67 kDa c-Myc protein in HL60 cells and lung carcinoma tissue.
Catalogue NumberOP10F
Brand Family Calbiochem®
References
ReferencesLeGouy, E., et al. 1987. In Nuclear Oncogenes, Cold Spring Harbor Laboratory, 144.
Cole, M.D. 1986. Ann. Rev. Gen. 20, 361.
Nisen, P.D., et al. 1986. Cancer Res. 46, 6217.
Nau, M.M., et al. 1985. Nature 318, 69.
Persson, H., et al. 1984. Science 225, 687.
Alitalo, K., et al. 1983. Proc. Natl. Acad. Sci. USA 80, 1707.
Product Information
FormLiquid
FormulationIn 50 mM sodium phosphate buffer, 0.2% gelatin.
Negative controlHT1080 cells
Positive controlHL-60 cells or lung carcinoma
Preservative≤0.1% sodium azide
Quality LevelMQ100
Applications
Application ReferencesEpitope Tagging Munro, S., et al. 1986. Cell 46, 291. Immunoblotting Evan, G.I., et al. 1985. Mol. Cell. Biol. 5, 3610.
Key Applications Flow Cytometry
Immunofluorescence
Application NotesFlow Cytometry (20 µg/ml)
Frozen Sections (use Cat. No. OP10, OP10L, or OP10T)
Immunoblotting (use Cat. No. OP10, OP10L, or OP10T)
Immunofluorescence (1-5 µg/ml)
Immunoprecipitation (use Cat. No. OP10, OP10L, or OP10T)
Paraffin Sections (use Cat. No. OP10, OP10L, or OP10T)
Application CommentsThe c-Myc protein is extremely labile. c-Myc degradation can be as a result of freeze/thaw cycles, thus, we recommend using fresh lysates with a cocktail of protease inhibitors. For immunoblotting, paraffin sections (colorimetric) Cat. No. OP10, OP10L, and OP10F are available. c-Myc is often destroyed during the processing of paraffin sections and can therefore be difficult to detect in this application. This antibody recognizes the c-Myc protein and its cleavage products. The sequence of c-Myc predicts a ~45 kDa protein, but c-Myc migrates under reducing conditions as a ~64-67 kDa band. This antibody will not detect v-Myc but may react weakly to rodent c-Myc when used at high concentrations (10 µg/ml). An extra ~34-40 kDa band may be detected in a immunoblot. May also be used in immunofluorescence as well as the detection and purification of recombinant proteins tagged with the Myc epitope sequence EQKLISEEDL (see application references). The immunogen, c-Myc (Peptide-1) is also available for competition studies (Cat. No. PP06). Antibody should be titrated for optimal results in individual systems.
Biological Information
Immunogena synthetic peptide (AEEQKLISEEDLLRKRREQLKHKLEQLRNSCA) corresponding to amino acids 408-439 of human c-Myc
ImmunogenHuman
Epitopewithin amino acids 410-419
Clone9E10
HostMouse
IsotypeIgG₁
Species Reactivity
  • Human
  • Mouse
  • Rat
Antibody TypeMonoclonal Antibody
Concentration Label Please refer to vial label for lot-specific concentration
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Blue Ice Only
Toxicity Standard Handling
Storage +2°C to +8°C
Protect from Light Protect from light
Do not freeze Yes
Packaging Information
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Catalogue Number GTIN
OP10F 0

Documentation

Anti-c-Myc (Ab-1) Mouse mAb (9E10) Fluorescein Conjugate SDS

Title

Safety Data Sheet (SDS) 

Anti-c-Myc (Ab-1) Mouse mAb (9E10) Fluorescein Conjugate Certificates of Analysis

TitleLot Number
OP10F

References

Reference overview
LeGouy, E., et al. 1987. In Nuclear Oncogenes, Cold Spring Harbor Laboratory, 144.
Cole, M.D. 1986. Ann. Rev. Gen. 20, 361.
Nisen, P.D., et al. 1986. Cancer Res. 46, 6217.
Nau, M.M., et al. 1985. Nature 318, 69.
Persson, H., et al. 1984. Science 225, 687.
Alitalo, K., et al. 1983. Proc. Natl. Acad. Sci. USA 80, 1707.

Brochure

Title
Caspases and other Apoptosis Related Tools Brochure
Data Sheet

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision02-October-2007 RFH
ApplicationFlow Cytometry (20 µg/ml)
Frozen Sections (use Cat. No. OP10, OP10L, or OP10T)
Immunoblotting (use Cat. No. OP10, OP10L, or OP10T)
Immunofluorescence (1-5 µg/ml)
Immunoprecipitation (use Cat. No. OP10, OP10L, or OP10T)
Paraffin Sections (use Cat. No. OP10, OP10L, or OP10T)
DescriptionPurified mouse monoclonal antibody generated by immunizing BALB/c mice with the specified immunogen and fusing splenocytes with SP2/0 mouse myeloma cells. Conjugated to FITC. Recognizes the ~64-67 kDa (apparent MW) c-Myc protein.
BackgroundThe v-myc oncogene, initially identified in the MC29 avian retrovirus, causes myelocytomas, carcinomas, sarcomas and lymphomas, and belongs to a family of oncogenes conserved throughout evolution. In humans the family consists of five genes: c-myc, N-myc, R-myc, L-myc, and B-myc. Amplification of the c-myc gene has been found in several types of human tumors including lung, breast and colon carcinomas, while the N-myc gene has been found amplified in neuroblastomas, small cell lung carcinomas and Wilms tumors. L-myc is amplified in small cell lung cancer. Immunological studies have shown that the human c-myc gene gives rise to at least two nuclear phosphoproteins of ~64 kDa and ~67 kDa that exhibit relatively short (30 min) half lives in vivo and exhibit DNA binding properties in vitro.
HostMouse
Immunogen speciesHuman
Immunogena synthetic peptide (AEEQKLISEEDLLRKRREQLKHKLEQLRNSCA) corresponding to amino acids 408-439 of human c-Myc
Epitopewithin amino acids 410-419
Clone9E10
IsotypeIgG₁
Specieshuman, mouse (weakly), rat (weakly)
Positive controlHL-60 cells or lung carcinoma
Negative controlHT1080 cells
FormLiquid
FormulationIn 50 mM sodium phosphate buffer, 0.2% gelatin.
Concentration Label Please refer to vial label for lot-specific concentration
Preservative≤0.1% sodium azide
CommentsThe c-Myc protein is extremely labile. c-Myc degradation can be as a result of freeze/thaw cycles, thus, we recommend using fresh lysates with a cocktail of protease inhibitors. For immunoblotting, paraffin sections (colorimetric) Cat. No. OP10, OP10L, and OP10F are available. c-Myc is often destroyed during the processing of paraffin sections and can therefore be difficult to detect in this application. This antibody recognizes the c-Myc protein and its cleavage products. The sequence of c-Myc predicts a ~45 kDa protein, but c-Myc migrates under reducing conditions as a ~64-67 kDa band. This antibody will not detect v-Myc but may react weakly to rodent c-Myc when used at high concentrations (10 µg/ml). An extra ~34-40 kDa band may be detected in a immunoblot. May also be used in immunofluorescence as well as the detection and purification of recombinant proteins tagged with the Myc epitope sequence EQKLISEEDL (see application references). The immunogen, c-Myc (Peptide-1) is also available for competition studies (Cat. No. PP06). Antibody should be titrated for optimal results in individual systems.
Storage Protect from light
+2°C to +8°C
Do Not Freeze Yes
Toxicity Standard Handling
ReferencesLeGouy, E., et al. 1987. In Nuclear Oncogenes, Cold Spring Harbor Laboratory, 144.
Cole, M.D. 1986. Ann. Rev. Gen. 20, 361.
Nisen, P.D., et al. 1986. Cancer Res. 46, 6217.
Nau, M.M., et al. 1985. Nature 318, 69.
Persson, H., et al. 1984. Science 225, 687.
Alitalo, K., et al. 1983. Proc. Natl. Acad. Sci. USA 80, 1707.
Application referencesEpitope Tagging Munro, S., et al. 1986. Cell 46, 291. Immunoblotting Evan, G.I., et al. 1985. Mol. Cell. Biol. 5, 3610.